| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $19.3M | — | +13.3% |
| SG&A Expense | $5.1M | — | -0.0% |
| Operating Income | -$24.4M | — | -10.2% |
| Net Income | -$23.5M | — | -15.8% |
| EPS (Basic) | -$0.95 | — | -14.5% |
| EPS (Diluted) | -$0.95 | — | -14.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $21.0M | -21.5% | -31.1% |
| Short-term Investments | $65.8M | -19.0% | -51.4% |
| Current Assets | $88.7M | -21.2% | -47.8% |
| Total Assets | $106.0M | -19.1% | -44.6% |
| Current Liabilities | $10.9M | -16.9% | -10.8% |
| Total Liabilities | $18.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.9M | — | -5.6% |
| Capital Expenditures | $242K | — | -52.6% |
| Investing Cash Flow | $15.3M | — | +53.6% |
| Financing Cash Flow | -$112K | — | -146.9% |
| Free Cash Flow | -$21.2M | — | -4.1% |
| -19.4% |
| Stockholders' Equity | $87.8M | -20.1% | -48.0% |